Lynch TJ et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 : 2129-2139, 2004
Rosell R et al : Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multi-centre, open-label, randomised phase 3 trial. Lancet Oncology 13 : 239-246, 2012
Zhou C et al : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study. Lancet Oncology 12 : 735-742, 2011